Filing Flows › Comparisons › NAMS vs XLO
NewAmsterdam Pharma Co N.V. vs Xilio Therapeutics: NAMS and XLO compared
NewAmsterdam Pharma Co N.V. is the larger company: $19.2M of revenue in its latest quarter (Q3 2026) against $18.7M for Xilio Therapeutics (Q2 2026). NewAmsterdam Pharma Co N.V. is growing faster (55× against +131% a year earlier). Xilio Therapeutics is more profitable, with an operating margin of -18.7% against -230.6%.
Where the money goes: NAMS and XLO
NewAmsterdam Pharma Co N.V. (NAMS) · Q3 2026
NewAmsterdam Pharma Co N.V., Q3 2026: revenue $19.2M (55× year over year), operating margin -230.6%, net loss $17.4M, operating cash flow −$39.8M. The chart follows the revenue to costs, profit and cash.
Xilio Therapeutics (XLO) · Q2 2026
Xilio Therapeutics, Q2 2026: revenue $18.7M (+131% year over year), operating margin -18.7%, net loss $6.4M, operating cash flow −$18.8M. The chart follows the revenue to costs, profit and cash.
| NewAmsterdam Pharma Co N.V. (NAMS) | Xilio Therapeutics (XLO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $19.2M | $18.7M |
| Revenue growth, Y/Y | 55× | +131% |
| Operating margin | -230.6% | -18.7% |
| Net earnings | −$17.4M | −$6.4M |
| Net margin | -90.7% | -34.1% |
| Operating cash flow | −$39.8M | −$18.8M |
Questions
Which is bigger, NewAmsterdam Pharma Co N.V. or Xilio Therapeutics?
NewAmsterdam Pharma Co N.V. is the larger company: $19.2M of revenue in its latest quarter (Q3 2026) against $18.7M for Xilio Therapeutics (Q2 2026).
Is NewAmsterdam Pharma Co N.V. or Xilio Therapeutics growing faster?
NewAmsterdam Pharma Co N.V. is growing faster (55× against +131% a year earlier).
Which is more profitable, NewAmsterdam Pharma Co N.V. or Xilio Therapeutics?
Xilio Therapeutics is more profitable, with an operating margin of -18.7% against -230.6%.
More: NewAmsterdam Pharma Co N.V. earnings · how NewAmsterdam Pharma Co N.V. makes money · Xilio Therapeutics earnings · how Xilio Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.